(Q36652214)

15 August 2017

1 reference

title

The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression (English)

1 reference

15 August 2017

1 reference

4

Laurence Zitvogel

0 references

François Ghiringhelli

series ordinal

1

object named as

Francois Ghiringhelli

0 references

François Martin

series ordinal

3

object named as

Francois Martin

1 reference

15 August 2017

Cédric Ménard

2

1 reference

15 August 2017

publication date

1 December 2006

1 reference

15 August 2017

published in

Immunological Reviews

1 reference

15 August 2017

volume

214

1 reference

15 August 2017

page(s)

229-238

1 reference

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Activating Ly-49 NK receptors: central role in cytokine and chemokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Interplay of natural killer cells and their receptors with the adaptive immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Differential antitumor immunity mediated by NKT cell subsets in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

A novel dendritic cell subset involved in tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Unravelling natural killer cell function: triggering and inhibitory human NK receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Immunology. A pathogen receptor on natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Natural killer cell receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

In vivo natural killer cell activities revealed by natural killer cell-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Natural killer cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

A proportion of patients with lymphoma may harbor mutations of the perforin gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Perspectives on cancer immuno-epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Regulatory T cells: key controllers of immunologic self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

A history of prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Functional maturation of CD4+CD25+CTLA4+CD45RA+ T regulatory cells in human neonatal T cell responses to environmental antigens/allergens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Autoreactive T cells in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

BCR/ABL promotes dendritic cell-mediated natural killer cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Pharmacology of imatinib (STI571).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Amino acid requirements for formation of the TGF-beta-latent TGF-beta binding protein complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Making sense of latent TGFbeta activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

Thrombospondin-1 is a major activator of TGF-beta1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2006.00445.X

10.1111/J.1600-065X.2006.00445.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference